Axicabtagene ciloleucel,Cyclophosphamide,Fludarabine
gilead
['axi-cel', 'dlbcl', 'zuma7']
os results from zuma7 presented at #asco2023 show 2l axi-cel improved os over soc (including 57% crossover to 3l cart). early referral of primary refractory/early relapsed dlbcl to a cart center is important! 
Assistant Professor @UWcarbone. #Lymphoma, #CLL, #survivorship. @MayoClinic @ClevelandClinic alum.